Atara Biotherapeutics (ATRA) Expected to Announce Earnings on Thursday

Atara Biotherapeutics (NASDAQ:ATRA) is expected to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Atara Biotherapeutics to post earnings of ($3.82) per share and revenue of $16.65 million for the quarter.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Friday, March 7th. The biotechnology company reported ($1.19) earnings per share for the quarter, beating the consensus estimate of ($3.82) by $2.63. The company had revenue of $32.75 million for the quarter, compared to the consensus estimate of $20.58 million. On average, analysts expect Atara Biotherapeutics to post $-10 EPS for the current fiscal year and $-10 EPS for the next fiscal year.

Atara Biotherapeutics Stock Performance

Shares of ATRA opened at $6.94 on Tuesday. The business has a 50-day moving average of $7.85 and a 200 day moving average of $9.69. Atara Biotherapeutics has a fifty-two week low of $5.40 and a fifty-two week high of $20.81. The firm has a market cap of $40.66 million, a P/E ratio of -0.27 and a beta of 0.49.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ATRA shares. HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a research note on Tuesday, January 28th. Rodman & Renshaw assumed coverage on shares of Atara Biotherapeutics in a research note on Friday, December 20th. They issued a “buy” rating and a $25.00 price target for the company. Canaccord Genuity Group reissued a “buy” rating and issued a $17.00 target price on shares of Atara Biotherapeutics in a research note on Tuesday, March 11th. TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Finally, RODMAN&RENSHAW downgraded shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 21st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $17.75.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.